<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="499">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <actrnumber>ACTRN12605000386639</actrnumber>
  <trial_identification>
    <studytitle>Frusemide infusion for the prevention of deterioration in renal function post cardiac surgery.</studytitle>
    <scientifictitle>Frusemide infusion for the prevention of deterioration in renal function post cardiac surgery.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Renal impairment after cardiac surgery.</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The  frusemide infusion group-  which will be monitored to achieve a trial specified hourly urine output target range of 1-2 ml/kg/hr. In order to achieve this target the patients may need to receive a loading dose of  frusemide  and may also require a frusemide infusion.   The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.</interventions>
    <comparator>The control group- which will receive frusemide bolus doses if required as determined by surgeon/consultant physician.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of increase in creatinine of 0.05 mmol/L or greater in the first 72 hours after cardiac surgery</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.the maximum change in serum creatinine from baseline value </outcome>
      <timepoint>During the first 7 days of hospital stay  </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.incidence of renal failure requiring any form of renal replacement therapy </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3.Duration of post-operative hospital and ICU stay.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4.the maximum Sequential Organ Failure Assessment (SOFA) score</outcome>
      <timepoint>In the first 7 days of hospital stay</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion from the pre-admission clinics, and wards of the Cardiothoracic surgery unit. Potential participants will be identified by daily review of planned cardiothoracic surgery schedules. Prior to inclusion in this study permission to approach patients will be obtained from involved treating Intensivists and Surgeons.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients will be excluded if:1.already in established dialysis dependent chronic renal failure.2.known allergy to frusemide. 3.age &lt; 184.Pregnant.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sequentially numbered opaque envelpoes</concealment>
    <sequence>A computer generated randomisation matrix.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>20/11/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Intensive Care Unit, RMH</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Intensive Care Research department Funding</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Belinda Howe</name>
      <address>Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427710</phone>
      <fax>+61 3 93428812</fax>
      <email>belinda.howe@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr J J Presneill</name>
      <address>Intensive Care Unit
Royal Melbourne Hospital
Grattan Street
Parkville VIC 3050</address>
      <phone>+61 3 93427441</phone>
      <fax>+61 3 93428812</fax>
      <email>jeffrey.presneill@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>